株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝線維症:世界の治験動向

Liver Fibrosis Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 244192
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.16円で換算しております。
Back to Top
肝線維症:世界の治験動向 Liver Fibrosis Global Clinical Trials Review, H2, 2016
出版日: 2016年11月30日 ページ情報: 英文 120 Pages
概要

当レポートでは、肝線維症に関する臨床研究の最新動向について分析しており、地域別の治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域

G7諸国における治験件数:肝線維症治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:肝線維症治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - 肝線維症 治療薬

有望な薬剤

  • 最新治験ニュース:肝線維症

治験プロファイルの基本情報

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3938CTIDB

GlobalData's clinical trial report, "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Liver Fibrosis Therapeutics Clinical Trials 27
  • Prominent Drugs 29
  • Latest Clinical Trials News on Liver Fibrosis 30
  • Nov 13, 2016: TRACON Pharmaceuticals Presents Clinical and Preclinical Data from Models of NASH and Liver Fibrosis at the 2016 AASLD Annual Meeting 30
  • Oct 12, 2016: ProMetic PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alstrom Syndrome 30
  • Sep 27, 2016: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis 31
  • Clinical Trial Profile Snapshots 33

Appendix 117

  • Abbreviations 117
  • Definitions 117
  • Research Methodology 118
  • Secondary Research 118
  • About GlobalData 119
  • Contact Us 119
  • Disclaimer 119
  • Source 120

List of Tables

List of Tables

  • Liver Fibrosis Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Liver Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Liver Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Liver Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Liver Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Liver Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
  • Liver Fibrosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
  • Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
  • Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
  • Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Liver Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
  • Liver Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Liver Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Liver Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures

List of Figures

  • Liver Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Liver Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Liver Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Liver Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Liver Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Liver Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
  • Liver Fibrosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
  • Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
  • Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Liver Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Liver Fibrosis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
  • Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Liver Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Liver Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Liver Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
  • Liver Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Liver Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Liver Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Liver Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
  • GlobalData Methodology 118
Back to Top